Related Experiment Video
Updated: Nov 18, 2025
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
18.5K
Rimegepant: acute treatment for migraine headaches
Golden L Peters1, Erin K Hennessey1
1Department of Pharmacy Practice, St. Louis College of Pharmacy, University of Health Sciences & Pharmacy in St Louis, 1 Pharmacy Place, St Louis, Missouri 63110, USA.
Pain Management
|February 8, 2021
Summary
Rimegepant offers a new acute treatment for migraine headaches, effectively reducing pain and symptoms. This medication is part of a new wave of migraine therapies targeting specific neurovascular pathways.
Area of Science:
- Neurology
- Pharmacology
Background:
- Migraine treatment is rapidly advancing with new acute and preventive options.
- Recent developments target the neurovascular hypothesis of migraine pathophysiology.
- Vasoactive peptides, like calcitonin gene-related peptide (CGRP), are key targets for novel migraine agents.
Purpose of the Study:
- To review recent advancements in migraine treatment.
- To highlight the role of CGRP in migraine pathophysiology.
- To discuss the efficacy and tolerability of rimegepant for acute migraine.
Main Methods:
- Review of recent clinical trials and pharmacological studies.
- Analysis of the mechanism of action for new migraine treatments.
- Evaluation of safety and efficacy data for rimegepant.
Main Results:
- Three new acute treatments (lasmiditan, rimegepant, ubrogepant) and four new preventive treatments (erenumab, fremanezumab, galcanezumab, eptinezumab) have been approved.
- Rimegepant effectively decreases pain and associated symptoms of acute migraine attacks.
- Rimegepant demonstrates good tolerability in adult patients with or without aura.
Conclusions:
- New migraine therapies are increasingly focused on the neurovascular pathway.
- Rimegepant represents a significant new option for acute migraine management.
- Targeting CGRP pathways offers a promising strategy for effective migraine relief.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
428
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
428
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
328
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
328
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
377
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
377
01:14Antiepileptic Drugs: Glutamate Antagonists
690
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
690
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
445
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
445
01:18Drug Delivery: Enteral Route
1.1K
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
1.1K